\-\ Texto\\:\\ \ \(0\)\
\-\ wbc\\-18\\.3\\,\\ multiple\\ viral\\ serologies\\ pending\ \(0\)\
\-\ csf\ \(2\)\
\-\ \\-\\-\\-\ \(165\)\
\-\ glucose\\-108\ \(1\)\
\-\ protein\\-21\\ \\(15\\-40\\)\ \(1\)\
\-\ wbc\\-0\ \(0\)\
\-\ rbc\\-0\ \(0\)\
\-\ no\\ organisms\ \(6\)\
\-\ no\\ growth\ \(12\)\
\-\ prominent\\ t2\\ hyperintense\\ areas\\ in\\ the\\ white\\ matter\\ with\\ focal\\ areas\\ of\\ enhancement\\ around\\ the\\ intrathecal\\ catheter\\ and\\ corpus\\ callosum\\.\ \(0\)\
\-\ methotrexate\\ induced\\ leukoencephalopathy\ \(1\)\
\-\ methotrexate\\ induced\\ leukoencephalopathy\ \(1\)\
\-\ viral\\ encephalopathy\ \(1\)\
\-\ adem\\ \\(acute\\ disseminated\\ encephalomyelitis\\)\ \(0\)\
\-\ pml\ \(0\)\
\-\ binswanger\\ disease\ \(0\)\
\-\ radiation\\ necrosis\ \(3\)\
\-\ patient\\ with\\ stage\\ iv\\ non\\-hodgkins\\ lymphoma\\ with\\ right\\ triceps\\ muscle\\ and\\ bilateral\\ lower\\ extremity\\ weakness\\ along\\ with\\ bilateral\\ hand\\ paresthesias\\.\\ \\ also\\ noted\\ to\\ have\\ a\\ recent\\ \\"decline\\ in\\ mental\\ status\\"\\ all\\ following\\ intrathecal\\ administration\\ of\\ methotrexate\\.\ \(0\)\
\-\ the\\ temporal\\ relationship\\ between\\ the\\ methotrexate\\ administration\\ and\\ onset\\ of\\ symptoms\\ with\\ mr\\ changes\\ and\\ normal\\ csf\\ fluid\\ analysis\\ suggests\\ that\\ methotrexate\\ is\\ the\\ culprit\\.\\ \\ however\\,\\ the\\ patient\\ does\\ have\\ a\\ white\\ count\\ and\\ viral\\ serologies\\ are\\ pending\\.\\ \\ the\\ areas\\ of\\ enhancement\\ are\\ likely\\ part\\ of\\ the\\ same\\ process\\ given\\ the\\ pericatheter\\ location\\ of\\ most\\ of\\ the\\ foci\\.\\ \\ some\\ of\\ the\\ foci\\,\\ however\\,\\ may\\ be\\ new\\ foci\\ of\\ nhl\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ methotrexate\\:\\ 0\\.15477905096534159\ \(0\)\
\-\ serologies\\:\\ 0\\.09229967322052901\ \(0\)\
\-\ intrathecal\\:\\ 0\\.07401060603377788\ \(0\)\
\-\ viral\\:\\ 0\\.07337486791107355\ \(0\)\
\-\ leukoencephalopathy\\:\\ 0\\.06733121211443562\ \(0\)\
\-\ foci\\:\\ 0\\.06252313546283599\ \(0\)\
\-\ induced\\:\\ 0\\.05825726102105184\ \(0\)\
\-\ wbc\\-18\\.3\\:\\ 0\\.050088172863446016\ \(0\)\
\-\ glucose\\-108\\:\\ 0\\.050088172863446016\ \(0\)\
\-\ protein\\-21\\:\\ 0\\.050088172863446016\ \(0\)\
\-\ wbc\\-0\\:\\ 0\\.050088172863446016\ \(0\)\
\-\ rbc\\-0\\:\\ 0\\.050088172863446016\ \(0\)\
\-\ binswanger\\:\\ 0\\.050088172863446016\ \(0\)\
\-\ areas\\:\\ 0\\.04901159950987614\ \(0\)\
\-\ pericatheter\\:\\ 0\\.046149836610264505\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.04460419654255392\ \(0\)\
\-\ 15\\-40\\:\\ 0\\.042211500357083\ \(0\)\
\-\ pending\\:\\ 0\\.042017325131247084\ \(0\)\
\-\ non\\-hodgkins\\:\\ 0\\.04094363927007044\ \(0\)\
\-\ culprit\\:\\ 0\\.04094363927007044\ \(0\)\
\-\ csf\\:\\ 0\\.040551072179613776\ \(0\)\
\-\ administration\\:\\ 0\\.04031432119208148\ \(0\)\
\-\ pml\\:\\ 0\\.03990772133374115\ \(0\)\
\-\ nhl\\:\\ 0\\.03990772133374115\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.03252543165118285\ \(0\)\
\-\ decline\\:\\ 0\\.03252543165118285\ \(0\)\
\-\ white\\:\\ 0\\.03220572968990929\ \(0\)\
\-\ paresthesias\\:\\ 0\\.031799105676694875\ \(0\)\
\-\ disseminated\\:\\ 0\\.0295715938143311\ \(0\)\
\-\ organisms\\:\\ 0\\.02942006968318246\ \(0\)\
\-\ adem\\:\\ 0\\.029272481692254843\ \(0\)\
\-\ relationship\\:\\ 0\\.028851413668654145\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.028587095398001347\ \(0\)\
\-\ triceps\\:\\ 0\\.02833452856521252\ \(0\)\
\-\ however\\:\\ 0\\.02703827335905762\ \(0\)\
\-\ enhancement\\:\\ 0\\.026028281433216317\ \(0\)\
\-\ callosum\\:\\ 0\\.024913077415472638\ \(0\)\
\-\ analysis\\:\\ 0\\.02471369491654497\ \(0\)\
\-\ suggests\\:\\ 0\\.02427399796418463\ \(0\)\
\-\ corpus\\:\\ 0\\.023922433170331856\ \(0\)\
\-\ bilateral\\:\\ 0\\.023566110560391408\ \(0\)\
\-\ part\\:\\ 0\\.023538009031276088\ \(0\)\
\-\ catheter\\:\\ 0\\.023329478537807754\ \(0\)\
\-\ mental\\:\\ 0\\.022654572083319304\ \(0\)\
\-\ growth\\:\\ 0\\.02111165906899034\ \(0\)\
\-\ count\\:\\ 0\\.02111165906899034\ \(0\)\
\-\ have\\:\\ 0\\.021027705435966954\ \(0\)\
\-\ stage\\:\\ 0\\.020710422891638332\ \(0\)\
\-\ around\\:\\ 0\\.02021604006783362\ \(0\)\
\-\ hyperintense\\:\\ 0\\.02015716059604074\ \(0\)\
\-\ same\\:\\ 0\\.02001257726842049\ \(0\)\
\-\ hand\\:\\ 0\\.019955758613110355\ \(0\)\
\-\ prominent\\:\\ 0\\.019927560946393714\ \(0\)\
\-\ temporal\\:\\ 0\\.019442561804625776\ \(0\)\
\-\ necrosis\\:\\ 0\\.019165344962754006\ \(0\)\
\-\ matter\\:\\ 0\\.01911636346818635\ \(0\)\
\-\ process\\:\\ 0\\.018693553891106333\ \(0\)\
\-\ weakness\\:\\ 0\\.018031882687661278\ \(0\)\
\-\ extremity\\:\\ 0\\.01775658505478658\ \(0\)\
\-\ iv\\:\\ 0\\.01771832350830167\ \(0\)\
\-\ muscle\\:\\ 0\\.017439291099013324\ \(0\)\
\-\ status\\:\\ 0\\.017331405233986668\ \(0\)\
\-\ location\\:\\ 0\\.016935839130135757\ \(0\)\
\-\ new\\:\\ 0\\.01691924986818499\ \(0\)\
\-\ given\\:\\ 0\\.016644399957479218\ \(0\)\
\-\ does\\:\\ 0\\.016566028809000037\ \(0\)\
\-\ recent\\:\\ 0\\.016322267322953395\ \(0\)\
\-\ along\\:\\ 0\\.01604576066396884\ \(0\)\
\-\ radiation\\:\\ 0\\.01593324573614964\ \(0\)\
\-\ mr\\:\\ 0\\.015427269726968377\ \(0\)\
\-\ between\\:\\ 0\\.015389179183092294\ \(0\)\
\-\ onset\\:\\ 0\\.015326256965483807\ \(0\)\
\-\ some\\:\\ 0\\.014743910533333859\ \(0\)\
\-\ changes\\:\\ 0\\.013915045319517389\ \(0\)\
\-\ lymphoma\\:\\ 0\\.013876128604485715\ \(0\)\
\-\ focal\\:\\ 0\\.013866440932604557\ \(0\)\
\-\ fluid\\:\\ 0\\.013799085821612803\ \(0\)\
\-\ following\\:\\ 0\\.013779987255120162\ \(0\)\
\-\ t2\\:\\ 0\\.013741981640627\ \(0\)\
\-\ all\\:\\ 0\\.013732519826314153\ \(0\)\
\-\ likely\\:\\ 0\\.01369482935190714\ \(0\)\
\-\ are\\:\\ 0\\.013237203096927292\ \(0\)\
\-\ symptoms\\:\\ 0\\.012100326573284881\ \(0\)\
\-\ acute\\:\\ 0\\.011987950733559632\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.01193258544108987\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.011703122170353653\ \(0\)\
\-\ noted\\:\\ 0\\.011508074934389738\ \(0\)\
\-\ most\\:\\ 0\\.011209290578000432\ \(0\)\
\-\ lower\\:\\ 0\\.010919670848658311\ \(0\)\
\-\ may\\:\\ 0\\.010649593005102976\ \(0\)\
\-\ multiple\\:\\ 0\\.010226170474314029\ \(0\)\
\-\ no\\:\\ 0\\.009777774439815931\ \(0\)\
\-\ patient\\:\\ 0\\.009733999214958955\ \(0\)\
\-\ also\\:\\ 0\\.009571702236762224\ \(0\)\
\-\ the\\:\\ 0\\.008640580293976612\ \(0\)\
\-\ that\\:\\ 0\\.008386254139538769\ \(0\)\
\-\ \\(\\:\\ 0\\.00820865598004387\ \(0\)\
\-\ \\)\\:\\ 0\\.008108382864923921\ \(0\)\
\-\ disease\\:\\ 0\\.00793600875690741\ \(0\)\
\-\ normal\\:\\ 0\\.007611434401131256\ \(0\)\
\-\ be\\:\\ 0\\.0074872541099086885\ \(0\)\
\-\ \\,\\:\\ 0\\.006152501489029258\ \(0\)\
\-\ of\\:\\ 0\\.005957580722624409\ \(0\)\
\-\ right\\:\\ 0\\.005122907438127368\ \(0\)\
\-\ and\\:\\ 0\\.005113892208301661\ \(0\)\
\-\ in\\:\\ 0\\.004788604887957443\ \(0\)\
\-\ a\\:\\ 0\\.004506815929756833\ \(0\)\
\-\ with\\:\\ 0\\.0033239822752809582\ \(0\)\
\-\ is\\:\\ 0\\.003194833968095032\ \(0\)\
\-\ to\\:\\ 0\\.0024265233434260583\ \(0\)\
\-\ \\.\\:\\ 0\\.0014119133675080905\ \(0\)\
